Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Mach7 Technologies ( (AU:M7T) ) is now available.
Mach7 Technologies announced the release of its Q1 FY26 results on 31 October 2025, followed by a webinar hosted by CEO Teri Thomas and CFO Dan Lee. This event provides an opportunity for investors to engage with the company’s leadership, reflecting Mach7’s commitment to transparency and stakeholder communication.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies (ASX:M7T) is a leading provider of medical imaging software, offering advanced data management and diagnostic viewing solutions to healthcare organizations globally. Their Mach7 Enterprise Imaging Solution (EIS) integrates a Vendor Neutral Archive, the eUnity Enterprise Diagnostic Viewer, and diagnostic workflow applications, catering to a wide range of healthcare providers from large networks to private practices.
Average Trading Volume: 242,137
Technical Sentiment Signal: Sell
Current Market Cap: A$69.32M
For an in-depth examination of M7T stock, go to TipRanks’ Overview page.